Congenital clinical anophthalmos and blind microphthalmos describe the absence of an eye or the presence of a small eye in the orbit. Between 1999 and 2013, 97 children with anophthalmos or microphthalmos were treated with self-inflating, hydrophilic gel expanders at the Rostock Eye Clinic. More than a decade later, this study investigated the perspective of patients and parents regarding the treatment, the surgical outcome, and the emotional and social well-being of the patients. A total of 22 families with 16 patients sighted in the other eye and six patients blind in both eyes participated. Questionnaires were developed, including items on physical, emotional, social, and medical aspects. The patients felt emotionally stable and integrated into their social environment, with no major limitations reported by the majority. These statements were confirmed by most of the parents. Parents (67%) indicated that the success of the operation was already apparent after the first intervention and that the current situation did not play a role in the patients' social environment. The study provided new insights into the therapy results, the postoperative care, and the social and emotional stability of the prosthesis-wearing patients, indicating the chosen expander methods as promising in terms of positive postoperative care.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856451 | PMC |
http://dx.doi.org/10.3390/children10010034 | DOI Listing |
Background: VY-TAU01 is a recombinant humanized IgG4 monoclonal antibody (mAb) directed against pathological tau for the treatment of patients with mild dementia or mild cognitive impairment due to Alzheimer's disease (AD). Both VY-TAU01 and its parental mouse IgG1 mAb Ab-01 target an epitope in the C-terminus of tau, bind pathological tau with high affinity and selectivity over wild-type tau, block paired helical filament seed-induced tau aggregates in vitro, and selectively stain tau tangles in AD and P301S mouse (C57/B6J-Tg[Thy1-MAPT*P301S]2541Godt) brain. Ab-01 robustly inhibits seeding and propagation of pathological tau in a P301S mouse seeding model.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Pittsburgh Alzheimer's Disease Research Center (ADRC), Pittsburgh, PA, USA.
Background: Black and African American adult males have the worst overall health than any other race or gender in the United States. The rate of Alzheimer's Disease is twice as high for Black and African American adults. Yet, little is known about how Black and African American adult males perceive the relationship between the social determinants of health and Alzheimer's Disease.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Pennsylvania, Philadelphia, PA, USA.
Background: Best practice recommendations suggest a person close to a patient with mild cognitive impairment (MCI) or dementia be involved in their care. This person is often referred to as a "caregiver," though the term "care partner" has increasingly been used in research and care instead of "caregiver." Unlike "caregiver," "care partner" suggests a collaborative relationship between the patient and their support person, in which the patient actively participates rather than passively receives help.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Neurogenetics Research Center, Instituto Nacional de Ciencias Neurológicas, Lima, Peru.
Background: Frontotemporal dementia (FTD) is a clinical syndrome characterized by progressive changes in behavior, executive function, or language. In Latin America, persons with FTD are underrecognized or diagnosed late. There is a lack of knowledge about the experiences have on families.
View Article and Find Full Text PDFCannabis
December 2024
Département des sciences de la santé, Université du Québec en Abitibi-Témiscamingue (UQAT).
Objective: An increase in medical cannabis and prescribed cannabinoids use for chronic pain management has been observed in Canada in the past years. This study aimed to: 1) Describe clinicians' perceived risk associated with the use of medical cannabis and prescribed cannabinoids for the management of chronic pain; and 2) Identify sociodemographic and professional factors associated with perceived risk of adverse effects.
Method: A web-based cross-sectional study was conducted in Quebec, Canada in 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!